Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

14.99 -0.04 (-0.27%)
Official Closing Price Updated: 6:30 PM EDT, Jun 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,729,588
Open 14.96
Bid (Size) 14.80 (39)
Ask (Size) 15.10 (1)
Prev. Close 15.03
Today's Range 14.92 - 15.01
52wk Range 12.57 - 15.43
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD
From Takeda Pharmaceutical Company Limited
Via Business Wire
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
From Takeda Pharmaceutical Company Limited
Via Business Wire

Performance

YTD
+13.1%
+13.1%
1 Month
-1.1%
-1.1%
3 Month
+6.5%
+6.5%
6 Month
+11.1%
+11.1%
1 Year
+14.3%
+14.3%

More News

Read More
Earnings Scheduled For May 8, 2025
Via Benzinga
Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award
From Takeda Pharmaceutical Company Limited
Via Business Wire
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1
From Takeda Pharmaceutical Company Limited
Via Business Wire
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
Via Investor's Business Daily
Topics Government Stocks
Exposures Political US Equities
Japanese Pharma Company Takeda Expects Limited Exposure To US-China Tariffs
Via Benzinga
Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress
From Takeda Pharmaceutical Company Limited
Via Business Wire
BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education
From Takeda Pharmaceutical Company Limited
Via Business Wire
UK's Health Agency Endorses Pfizer's Blood Cancer Combo Therapy As First For Untreated Hodgkin Lymphoma Patients
Via Benzinga
Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan
Via Benzinga
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
Via Benzinga
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
Via Benzinga
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
From Takeda Pharmaceutical Company Limited
Via Business Wire
Earnings Scheduled For January 30, 2025
Via Benzinga
Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth
From Takeda Pharmaceutical Company Limited
Via Business Wire
Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights
Via Benzinga
FDA Bans Red Dye No. 3 Effective January 2027, Cites Cancer Risks: Food Stocks To Watch
Via Benzinga
Exposures Product Safety
Takeda's HYQVIA Approved in Japan To Treat Immunodeficiency
Via Benzinga
Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
From Takeda Pharmaceutical Company Limited
Via Business Wire
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Via Benzinga
HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)
From HUTCHMED (China) Limited
Via GlobeNewswire
Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas
From Takeda Pharmaceutical Company Limited
Via Business Wire

Frequently Asked Questions

Is Takeda Pharmaceutical Company Limited American Depositary Shares (each publicly traded?
Yes, Takeda Pharmaceutical Company Limited American Depositary Shares (each is publicly traded.
What exchange does Takeda Pharmaceutical Company Limited American Depositary Shares (each trade on?
Takeda Pharmaceutical Company Limited American Depositary Shares (each trades on the New York Stock Exchange
What is the ticker symbol for Takeda Pharmaceutical Company Limited American Depositary Shares (each?
The ticker symbol for Takeda Pharmaceutical Company Limited American Depositary Shares (each is TAK on the New York Stock Exchange
What is the current price of Takeda Pharmaceutical Company Limited American Depositary Shares (each?
The current price of Takeda Pharmaceutical Company Limited American Depositary Shares (each is 14.99
When was Takeda Pharmaceutical Company Limited American Depositary Shares (each last traded?
The last trade of Takeda Pharmaceutical Company Limited American Depositary Shares (each was at 06/05/25 06:30 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.